OTCBB Biotechnology Stock

Penny Biotechnology Stock

AMEX Biotechnology Stock

Hot Biotechnology Stock

NYSE Biotechnology Stock

NASDAQ Biotechnology Stock

Biotechnology Stock

ACADIA Pharmaceuticals Inc.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently have five programs in clinical development and several additional programs in preclinical development and discovery stages. In our most advanced proprietary program, we are entering Phase III development ... more

Accelrys, Inc.

We develop and commercialize software for computation, simulation, management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Our technology and services are designed to meet the needs of today’s leading research organizations. We are headquartered in ... more

Acorda Therapeutics, Inc.

We have a history of operating losses and we expect to continue to incur losses and may never be profitable. As of December 31, 2005, we had an accumulated deficit of approximately $208.0 million. We had net losses of $35.5 million and $44.7 million for the years ended December 31, 2005 and December 31, 2004, respectively. We have had operating losses since ... more

Affymetrix, Inc.

Overview We are engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets and are recognized as a market leader in creating breakthrough tools that are advancing our understanding of the molecular basis of life. The markets for our products currently include all aspects of molecular biology ... more

Agenus Inc.

Antigenics Inc. (including its subsidiaries, also referred to in this Annual Report on Form 10-K as “Antigenics”, the “Company”, “we”, “us”, and “our”) is a biotechnology company developing technologies and products to treat cancers and infectious diseases, primarily based on immunological approaches. Our most advanced product ... more

Albany Molecular Research, Inc.

Overview Albany Molecular Research, Inc. (“the Company”), a Delaware corporation incorporated on June 20, 1991, is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market. Our core business consists of a fee-for service contract services platform ... more

Alexion Pharmaceuticals, Inc.

We are a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. We are engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Since our incorporation in ... more

Allos Therapeutics, Inc.

Strategy Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners. The key elements of our business strategy are to: ·        Focus on the oncology market. We intend to continue to focus our drug development efforts on the oncology market. We ... more

Amylin Pharmaceuticals, Inc.

School Health Industry Advisory Board, the Harvard Business School Dean’s Advisory Board, the Advisory Board for the Kellogg Center for Executive Women, and the University of California, San Diego Health Sciences Advisory Board. Ms. Graham received an M.B.A. from Harvard University. Mr. Bradbury has served as our President and Chief Operating Officer since June 2006, serving as our ... more

Arena Pharmaceuticals, Inc.

We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our most advanced drug candidate, lorcaserin hydrochloride, or lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. ... more

ARIAD Pharmaceuticals, Inc.

, OUR FINANCIAL CONDITION AND OUR RESULTS OF OPERATIONS. Risks Relating to Our Business We have only one product candidate in clinical trials, AP23573, and we and our partners may never succeed in developing marketable products or generating product revenues. We are a biopharmaceutical company focused on the discovery and development of drugs ... more

ArQule, Inc.

STRATEGY Development of our products is at an early stage and is based on scientific platforms that are unproven. We may not successfully develop a drug candidate that becomes a commercially viable drug. The discovery and development of drugs is inherently risky and involves a high rate of failure. Discovering and developing commercial drugs are relatively new to us. Our drug candidates ... more

Array BioPharma Inc.

We have a history of losses and may not achieve or sustain profitability. We are at an early stage of executing our business plan, and we have a limited history of developing and out-licensing our proprietary drug candidates and offering our drug discovery capabilities. We have incurred significant operating and net losses and negative cash flows from operations since our inception. As of ... more

Bioanalytical Systems, Inc.

The Company operates in two business segments – contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. Both segments arose out of the Company’s expertise in a number of core technologies designed to quantify trace chemicals in complex matrices. The Company evaluates performance and ... more

BioCryst Pharmaceuticals, Inc.

" -->ITEM 1. BUSINESSForward-Looking Statements and Risk Factors     This report includes forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. We have based these forward-looking statements on our current ... more